Fusion Pharmaceuticals Inc

NASDAQ:FUSN   4:00:00 PM EDT
2.29
+0.02 (+0.88%)
6:21:24 PM EDT: $2.28 -0.01 (-0.44%)
Earnings Announcements

Fusion Pharmaceuticals Announces Third Quarter Financial Results

Published: 11/08/2022 13:01 GMT
Fusion Pharmaceuticals Inc (FUSN) - Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates.
Fpi-1434 Phase 1 Data on Track to Be Reported in First Half of 2023.
Phase 1/2 Study of Fpi-1966 Open and Enrolling Patients With Solid Tumors Expressing Fgfr3.
Fusion Pharmaceuticals - Expects Existing Cash, Cash Equivalents,investments As of Sept 30, 2022, to Be Sufficient to Fund Operations Into Q3 of 2024.
For Q3 of 2022, Fusion Reported a Net Loss of $24.0 Million, Or $0.55 per Share.
Q3 Earnings per Share View $-0.50 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.02 Million
Adjusted EPS is expected to be -$0.55

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.51

More details on our Analysts Page.